(OPCH) Option Care Health - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68404L2016

Infusion, Nutrition, Immunotherapy, Neurological

Health Care Services
Market Cap in USD: 5,161m

IPO / Inception: 1996-08-15
12m vs SPY: 3.83%

EPS (Earnings per Share)

EPS CAGR: -39.48%
EPS Trend: 20.1%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 12.35%
Rev. Trend: 98.8%

Last SUE: 0.98
Qual. Beats: 8

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	51.8%
Value at Risk 5%th	79.9%
Relative Tail Risk	-6.26%

Reward TTM
Sharpe Ratio	0.77
Alpha	35.34
CAGR/Max DD	0.18

Character TTM
Hurst Exponent	0.268
Beta	0.322
Beta Downside	0.278

Drawdowns 3y
Max DD	38.67%
Mean DD	12.69%
Median DD	11.03%

Description: OPCH Option Care Health January 08, 2026

Option Care Health, Inc. (NASDAQ: OPCH) delivers a broad portfolio of home- and alternate-site infusion therapies across the United States, covering anti-infectives, cardiac failure treatments, parenteral and enteral nutrition, immunoglobulins, chronic inflammatory diseases (e.g., Crohn’s, rheumatoid arthritis), neurological disorders (e.g., Duchenne muscular dystrophy, multiple sclerosis), bleeding disorders, high-risk pregnancy care, and supportive services such as pain management, chemotherapy, and respiratory medication administration. The company sources patients primarily through referrals from physicians, hospital discharge planners, health-maintenance organizations (HMOs), and preferred provider organizations (PPOs), and is headquartered in Bannockburn, Illinois.

Recent SEC filings (Q2 2024) show OPCH generated $1.03 billion in revenue, a 12% year-over-year increase driven by a 15% rise in home-infusion patient volume and higher reimbursement rates for specialty drugs. The business benefits from macro trends such as the U.S. shift toward outpatient care (home-health market projected to grow > 7% CAGR through 2028) and an aging population that expands demand for chronic-disease management. However, the companys margins remain sensitive to payer mix changes and drug pricing volatility, which have historically introduced ± 3% swings in adjusted EBITDA margin.

If you want a data-rich, independent perspective on OPCH’s valuation and risk profile, consider reviewing the analyst tools available on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (209.2m TTM) > 0 and > 6% of Revenue (6% = 331.8m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA -1.41pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 8.30% (prev 11.69%; Δ -3.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 258.7m > Net Income 209.2m (YES >=105%, WARN >=100%)

Net Debt (966.4m) to EBITDA (458.4m) ratio: 2.11 <= 3.0 (WARN <= 3.5)

Current Ratio 1.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (164.6m) change vs 12m ago -4.27% (target <= -2.0% for YES)

Gross Margin 19.41% (prev 20.76%; Δ -1.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 160.1% (prev 139.3%; Δ 20.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 3.35 (EBITDA TTM 458.4m / Interest Expense TTM 117.2m) >= 6 (WARN >= 3)

Altman Z'' 2.80

(A) 0.13 = (Total Current Assets 1.28b - Total Current Liabilities 823.9m) / Total Assets 3.48b

(B) 0.24 = Retained Earnings (Balance) 818.4m / Total Assets 3.48b

(D) 0.39 = Book Value of Equity 823.9m / Total Liabilities 2.12b

Total Rating: 2.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 72.84

1. Piotroski 6.50pt

2. FCF Yield 4.05%

3. FCF Margin 4.49%

4. Debt/Equity 0.94

5. Debt/Ebitda 2.11

6. ROIC - WACC (= 5.31)%

7. RoE 15.29%

8. Rev. Trend 98.80%

9. EPS Trend 20.12%

What is the price of OPCH shares?

As of January 14, 2026, the stock is trading at USD 34.75 with a total of 5,366,476 shares traded.
Over the past week, the price has changed by +5.98%, over one month by +3.61%, over three months by +30.30% and over the past year by +25.36%.

Is OPCH a buy, sell or hold?

Option Care Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy OPCH.

Strong Buy: 6
Buy: 3
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the OPCH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	36.9	6.2%
Analysts Target Price	36.9	6.2%
ValueRay Target Price	35	0.7%

OPCH Fundamental Data Overview January 13, 2026

P/E Trailing = 25.2381
P/E Forward = 18.622
P/S = 0.9332
P/B = 3.7152
P/EG = 1.6051
Beta = 0.805
Revenue TTM = 5.53b USD
EBIT TTM = 392.7m USD
EBITDA TTM = 458.4m USD
Long Term Debt = 1.16b USD (from longTermDebt, last quarter)
Short Term Debt = 30.3m USD (from shortTermDebt, last quarter)
Debt = 1.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 966.4m USD (from netDebt column, last quarter)
Enterprise Value = 6.13b USD (5.16b + Debt 1.28b - CCE 309.8m)
Interest Coverage Ratio = 3.35 (Ebit TTM 392.7m / Interest Expense TTM 117.2m)
EV/FCF = 24.67x (Enterprise Value 6.13b / FCF TTM 248.3m)
FCF Yield = 4.05% (FCF TTM 248.3m / Enterprise Value 6.13b)
FCF Margin = 4.49% (FCF TTM 248.3m / Revenue TTM 5.53b)
Net Margin = 3.78% (Net Income TTM 209.2m / Revenue TTM 5.53b)
Gross Margin = 19.41% ((Revenue TTM 5.53b - Cost of Revenue TTM 4.46b) / Revenue TTM)
Gross Margin QoQ = 19.02% (prev 19.00%)
Tobins Q-Ratio = 1.76 (Enterprise Value 6.13b / Total Assets 3.48b)
Interest Expense / Debt = 5.62% (Interest Expense 71.7m / Debt 1.28b)
Taxrate = 24.87% (17.2m / 69.0m)
NOPAT = 295.0m (EBIT 392.7m * (1 - 24.87%))
Current Ratio = 1.56 (Total Current Assets 1.28b / Total Current Liabilities 823.9m)
Debt / Equity = 0.94 (Debt 1.28b / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = 2.11 (Net Debt 966.4m / EBITDA 458.4m)
Debt / FCF = 3.89 (Net Debt 966.4m / FCF TTM 248.3m)
Total Stockholder Equity = 1.37b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.06% (Net Income 209.2m / Total Assets 3.48b)
RoE = 15.29% (Net Income TTM 209.2m / Total Stockholder Equity 1.37b)
RoCE = 15.56% (EBIT 392.7m / Capital Employed (Equity 1.37b + L.T.Debt 1.16b))
RoIC = 11.84% (NOPAT 295.0m / Invested Capital 2.49b)
WACC = 6.53% (E(5.16b)/V(6.44b) * Re(7.10%) + D(1.28b)/V(6.44b) * Rd(5.62%) * (1-Tc(0.25)))
Discount Rate = 7.10% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.77%
[DCF Debug] Terminal Value 86.17% ; FCFF base≈266.2m ; Y1≈327.1m ; Y5≈551.8m
Fair Price DCF = 77.29 (EV 13.23b - Net Debt 966.4m = Equity 12.27b / Shares 158.7m; r=6.53% [WACC]; 5y FCF grow 24.45% → 2.90% )
EPS Correlation: 20.12 | EPS CAGR: -39.48% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.80 | Revenue CAGR: 12.35% | SUE: 0.98 | # QB: 8
EPS next Quarter (2026-03-31): EPS=0.41 | Chg30d=-0.005 | Revisions Net=-1 | Analysts=8
EPS next Year (2026-12-31): EPS=1.88 | Chg30d=+0.005 | Revisions Net=+0 | Growth EPS=+9.6% | Growth Revenue=+7.5%

Additional Sources for OPCH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle